The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice
Open accessThe DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated viruses (AAVs) have been used widely for in vivo gene therapy. However, adaptive immune responses to AAV have posed a significant hurdle in clinical application of AAV vectors. Recent advances have suggested a crucial role for innate immunity in shaping adaptive immune responses. How AAV activates innate immunity, and thereby promotes AAV-targeted adaptive immune responses, remains unknown. Here we show that AAV activates mouse plasmacytoid DCs (pDCs) via TLR9 to produce type I IFNs. In vivo, the TLR9-MyD88 pathway was crucial to the activation of CD8+ T cell responses to both the transgene product and the AAV capsid, leading to loss of transgene expression and the generation of transgene product-specific and AAV-neutralizing antibodies. We further demonstrate that TLR9-dependent activation of adaptive immunity targeting AAV was mediated by type I IFNs and that human pDCs could be activated in vitro to induce type I IFN production via TLR9. These results reveal an essential role for the TLR9-MyD88-type I IFN pathway in induction of adaptive immune responses to AAV and suggest that strategies that interfere with this pathway may improve the outcome of AAV-mediated gene therapy in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We confirmed with Myd88−/− mice that development of CD8+ T cell responses against rh32.33 capsid depended on MyD88(15, 17) (Fig. 2A, middle panel).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We confirmed with Tlr9−/− and Myd88−/− mice that the innate immune response to self-complementary AAV was indeed dependent on the TLR9/MyD88 pathway (Fig. 1D and 1E), as previously shown in the literature (15–17).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglia are the chief resident immune cells of the retina and are capable of inducing pro-inflammatory cytokine expression through TLR9- and TLR2-mediated responses,41 which have been demonstrated to detect AAV genomes and capsids, respectively.42, 43, 44”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unmethylated CpG elements elicit innate immunity and CTL response through TLR9/MyD88-dependent pathway (23).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous animal studies have shown the immune-activating effects of CpG motifs in AAV (23, 150, 151).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [23]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood
Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S., & Liu, Y.-J. (1999) · Science · doi:10.1126/science.284.5421.1835 · Cited by 2,293
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Innate immune recognition of viral infection
Kawai, T., & Akira, S. (2006) · Nature Immunology · doi:10.1038/ni1303 · Cited by 1,899
Recognition of single-stranded RNA viruses by Toll-like receptor 7
Lund, J. M., Alexopoulou, L., Sato, A., Karow, M., Adams, N. C., Gale, N. W., Iwasaki, A., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400937101 · Cited by 1,861
Plasmacytoid dendritic cells in immunity
Colonna, M., Trinchieri, G., & Liu, Y.-J. (2004) · Nature Immunology · doi:10.1038/ni1141 · Cited by 1,678
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Dzionek, A., Fuchs, A., Schmidt, P., Cremer, S., Zysk, M., Miltenyi, S., Buck, D. W., & Schmitz, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6037 · Cited by 1,298
Cited by
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“30,31 AAV vectors also trigger nuclear factor k B – dependent production of cytokine and chemokine release in mouse liver, 32 and MyD88 signaling in B cells also seems to control the production of capsid-speci fi c T helper 1 antibody responses.”
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“112,424,428 Depletion of CpG motifs from a rAAV8-based vector to treat hemophilia B led to reduced NAb development.”
BackgroundEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
“29,30 The timing and features of the toxicity noted in this NHP cohort are reminiscent of the innate immune response to high systemic doses of adenoviral vectors that resulted in lethal systemic inflammation in one research subject.”
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“AAV vectors activate T1 IFN expression in human and murine pDCs but not in CD11c conventional DCs (cDCs).(67) T1 IFN production is the result of TLR9-myeloid differentiation primary response protein 88 (MyD88) signaling in pDCs and promotes activation of CD8 T cells.”
BackgroundToll-Like Receptors in Antiviral Innate Immunity
Lester, S. N., & Li, K. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.11.024 · Cited by 735
“Recently, it has been shown that AAV vectors activate pDCs via the TLR9-MyD88 pathway to produce type I IFNs, which drive up both CD8+ T cell and antibody responses leading to loss of transgene expression in vivo [150].”
BackgroundProgress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
AAV-Mediated Gene Therapy for Research and Therapeutic Purposes
Samulski, R. J., & Muzyczka, N. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085355 · Cited by 551
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Immunogenicity and toxicity of AAV gene therapy
Ertl, H. C. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975803 · Cited by 402
“Compared to other viruses, AAVs or vectors based on AAVs, only elicit modest inflammatory responses, which can be triggered by TLR9 binding to unmethylated CpG sequences within the vectors’ genome (49), by a PAMP within the capsid proteins that binds to TLR2 (50) and potentially by double stranded RNA, which could int…”
BackgroundAAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
“200,203 Interestingly, Rogers et al. demonstrated that activation of TLR9-MyD88 pathway in plasmacy-toid dendritic cells (pDC) is essential for the cross-priming of capsid-speci fi c CD8+ T cells, in a complex process that also requires a cross-talk with conventional DC (cDC) and type I interferon…”
BackgroundHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
“TLR9 in either Kupffer cells (69), peripheral plasmacytoid DCs (pDCs) (66, 70) or monocyte-derived DCs (71).”
BackgroundKeeler, A. M., & Flotte, T. R. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015530 · Cited by 322
CpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254
“Previous reports revealed that innate immune recognition of the serotype AAV2 by plasmacytoid dendritic cells was mediated by TLR9 and dependent on MyD88 signaling, independent of the form of transgene (16).”
AAV cis -regulatory sequences are correlated with ocular toxicity
Xiong, W., Wu, D. M., Xue, Y., Wang, S. K., Chung, M. J., Ji, X., Rana, P., Zhao, S. R., Mai, S., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821000116 · Cited by 249
Martino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Unraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
“In vitro studies indicate that rAAV vectors carrying a single-stranded DNA genome interact with the innate immune system through the Toll-like receptor (TLR)9/MyD88 and type I interferon cascades.(97) Additionally, the capsid of AAV2 may also interact with the innate immune system via TLR2 in liver non-parenchymal cel…”
BackgroundA Virological View of Innate Immune Recognition
Iwasaki, A. (2012) · Annual Review of Microbiology · doi:10.1146/annurev-micro-092611-150203 · Cited by 217
Hösel, M., Broxtermann, M., Janicki, H., Esser, K., Arzberger, S., Hartmann, P., Gillen, S., Kleeff, J., Stabenow, D., Odenthal, M., et al. (2012) · Hepatology · doi:10.1002/hep.24625 · Cited by 219
“This sensor is highly expressed on plasmacytoid dendritic cells (pDCs) that produce high levels of type I IFN in response to rAAV infection.(4) Approximately 70% of the liver is composed of hepatocytes, whereas the remaining nonparenchymal liver cells (NPCs) are mainly represented by liver sinusoidal endothelial cells…”
BackgroundAdeno-Associated Virus Technologies and Methods for Targeted Neuronal Manipulation
Haery, L., Deverman, B. E., Matho, K. S., Cetin, A., Woodard, K., Cepko, C., Guerin, K. I., Rego, M. A., Ersing, I., Bachle, S. M., et al. (2019) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2019.00093 · Cited by 211
Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215
“Innate immune responses, such as interferon induction, trigger an antiviral state among cells, while inflammation recruits other immune cells to the site of infection and primes adaptive immune responses (15, 16).”
BackgroundInfluentialWang, L., Calcedo, R., Bell, P., Lin, J., Grant, R. L., Siegel, D. L., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.031 · Cited by 212
“Much is being learned about host–vector interactions, such as the role of innate immunity and the activation of T cells and B cells in response to the vector and its transgene product (Manno et al. , 2006; Cao et al. , 2007; Mingozzi et al. , 2007; Zhu et al. , 2009).”
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
“Additional preclinical studies are also needed to better predict safer doses and biomarkers of toxicity, as well as the influence of parameters like empty capsid levels, impurities resulting from manufacturing methods, mice revealed that only pDCs were capable of producing type I IFNs in response to AAV, which in turn…”
BackgroundMingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Konkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., et al. (2021) · Blood · doi:10.1182/blood.2019004625 · Cited by 189
Innate Immune Responses to AAV Vectors
Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178
“Nonetheless, in TLR9−/− mice, AAV2–influenza hemagglutinin (HA) gene transfer to skeletal muscle exhibits diminished responses against HA (Zhu et al., 2009).”
BackgroundInfluentialAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
“TLR9 -dependent and -independent signaling triggers MyD88 phosphorylation, which is a critical step in activation of cytotoxic T cells (CTLs) reactive to viral capsids (17–19).”
BackgroundSutlu, T., Nyström, S., Gilljam, M., Stellan, B., Applequist, S. E., & Alici, E. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.080 · Cited by 162
“, 1997; Liu and Muruve 2003), AAV (Zaiss et al., 2002; Zhu et al., 2009), baculovirus (Hervas-Stubbs et al.”
Marchant, D., Singhera, G. K., Utokaparch, S., Hackett, T. L., Boyd, J. H., Luo, Z., Si, X., Dorscheid, D. R., McManus, B. M., & Hegele, R. G. (2010) · Journal of Virology · doi:10.1128/jvi.00804-10 · Cited by 160
“For instance, MyD88 deficiency in the host organism results in greater viral loads/viremia (4, 7, 41, 50), due to a lack”
BackgroundMartino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Furthermore, the TLR9/ MyD88 pathway is not only vital for mounting a CD8+ T-cell response against the AAV capsid but also liver and muscle-directed transgenes [28, 34, 35, 41].”
BackgroundSalabarria, S. M., Corti, M., Coleman, K. E., Wichman, M. B., Berthy, J. A., D’Souza, P., Tifft, C. J., Herzog, R. W., Elder, M. E., Shoemaker, L. R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173510 · Cited by 159
“AAV particles are a potent activator of the innate immune system, not only through the physical properties of the capsid particle, but also through the response to the high capsid protein load associated with systemic AAV administration (11–13).”
BackgroundDurability of transgene expression after rAAV gene therapy
Muhuri, M., Lévy, D., Schulz, M., McCarty, D. M., & Gao, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.004 · Cited by 172
“In particular, mouse studies suggest that the Toll-like receptor 9 (TLR9)/myeloid differentiation factor 88 pathway is critical for priming the CD8 cytotoxic T lymphocyte (CTL) response to the rAAV capsid and the transgene product.(86,87) Unlike that in wild-type mice, administration of an immunogenic AAVrh32.”
BackgroundYao, X., Carlson, D., Sun, Y., Ma, L., Wolf, S. E., Minei, J. P., & Zang, Q. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139416 · Cited by 145
“We next examined whether sepsis alters the expression of TLR9 and related response factors, such as myeloid differentiation primary response protein MYD88 [60, 61] and IL-1R-associated kinase–4 (IRAK4) [62].”
BackgroundExploiting viral sensing mediated by Toll-like receptors to design innovative vaccines
Sartorius, R., Trovato, M., Manco, R., D’Apice, L., & De Berardinis, P. (2021) · npj Vaccines · doi:10.1038/s41541-021-00391-8 · Cited by 131
Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
Feldman, A. G., Parsons, J. A., Dutmer, C. M., Veerapandiyan, A., Hafberg, E., Maloney, N., & Mack, C. L. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.05.044 · Cited by 136
Moreno, A. M., Palmer, N., Alemán, F., Chen, G., Pla, A., Jiang, N., Leong Chew, W., Law, M., & Mali, P. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0431-2 · Cited by 125
Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131
“TLR9 signaling in general is more connected to activation of CD8+ T cells than to B cell responses against AAV.13,15,18,19 This pathway appears be uniquely responsible for inducing capsid-specific CD8+ T cells, while an alternative activation signal via TLR4 cannot compensate for the lack of TLR9.”
InfluentialThe Complex and Evolving Story of T cell Activation to AAV Vector-encoded Transgene Products
Mays, L. E., & Wilson, J. M. (2011) · Molecular Therapy · doi:10.1038/mt.2010.250 · Cited by 125
Uto, T., Akagi, T., Yoshinaga, K., Toyama, M., Akashi, M., & Baba, M. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.052 · Cited by 141
Myerson, J. W., Patel, P., Rubey, K. M., Zamora, M. E., Zaleski, M. H., Habibi, N., Walsh, L. R., Lee, Y.-W., Luther, D. C., Ferguson, L. T., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00997-y · Cited by 132
Adeno-associated Virus Vectors in Gene Therapy
Mary, B., Khan, N., Arumugam, S., Saxena, H., Kumar, M., Manimaran, P., Chattopadhyay, S., & Jayandharan, G. R. (2018) · Springer eBooks · doi:10.1007/978-981-13-0481-1_2 · Cited by 127
Adeno-Associated Virus (AAV) Versus Immune Response
Rabinowitz, J., Chan, Y. K., & Samulski, R. J. (2019) · Viruses · doi:10.3390/v11020102 · Cited by 122
“revealed that innate immune recognition of AAV2 by mouse or human plasmacytoid dendritic cells (pDCs) was mediated by TLR9, dependent on MyD88 signaling, and was independent of the form of transgene or capsid serotype [13].”
BackgroundImmunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
“, lasting only as short as about 6 h after exposure), but could lead to enhanced adaptive immune responses.(26,27) This type of immunologic response, however, is highly dependent on the components (e.”
BackgroundTargeting the TLR9–MyD88 pathway in the regulation of adaptive immune responses
Huang, X., & Yang, Y. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.501333 · Cited by 121
“In vivo, the TLR9--MyD88 pathway is crucial to the activation of CD8 T cell responses to both the transgene product and the AAV vector, leading to loss of transgene expression, and the generation of anti-transgene and AAV-neutralizing antibodies [29].”
BackgroundResultSelf-citationShao, W., Earley, L. F., Chai, Z., Chen, X., Sun, J., He, T., Deng, M., Hirsch, M. L., Ting, J., Samulski, R. J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120474 · Cited by 119
“The high expression of IFN-β at day 1 of AAV transduction in some primary human hepatocytes may result from the TLR9-mediated innate immune response but not from the TLR2 pathway, as suggested by early studies (18, 19).”
BackgroundMethodResultInfluentialChallenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
Hamilton, B. A., & Wright, J. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675897 · Cited by 117
Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution
Grimm, D., & Büning, H. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.172 · Cited by 112
“28,29 Of note, innate immune responses are not restricted to conventional immune cells.”
Hareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
“The induction of this endosomal PRR pathway was independent of the transgene or AAV serotype [27].”
BackgroundInfluentialPerez, B. A., Shutterly, A., Chan, Y. K., Byrne, B. J., & Corti, M. (2020) · Brain Sciences · doi:10.3390/brainsci10020119 · Cited by 112
“TLR9 has been implicated in immune recognition of AAVs by binding to unmethylated CpG motifs in the AAV genome and activating signaling adaptor protein, myeloid differentiation primary response gene 88 (MyD88) [86].”
BackgroundEarley, L. F., Conatser, L. M., Lue, V. M., Dobbins, A. L., Li, C., Hirsch, M. L., & Samulski, R. J. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.274 · Cited by 111
“were able to eliminate the CGI in the hairpins arms and still produce vector, so some CpG depletion is certainly viable but interpreting this effect on transcription alone could be complicated by innate immune pathways such as TLR9.(41,42)”
BackgroundEngineering the AAV capsid to evade immune responses
Barnes, C., Scheideler, O., & Schaffer, D. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.002 · Cited by 102
“The two innate pathways previously been shown to be active are the TLR9- and TLR2-MyD88, which both stimulate the production of interferons.[12], [13] While the primary focus has been on the acute postinfection response, recent work has shown that double-stranded RNA (dsRNA) can activate dsRNA sensor MDA5 and trigger…”
BackgroundEnhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
Bartel, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00204 · Cited by 108
“Only recently, Zhu et al. (2009) provided evidence that AAV’s genome is recognized by the innate immune system through the Toll-like receptor 9-MyD88 pathway.”
BackgroundExposure to wild-type AAV drives distinct capsid immunity profiles in humans
Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122372 · Cited by 104
Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
Immune Response Mechanisms against AAV Vectors in Animal Models
Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97
“Transgene product acquired from transduced muscle cells is crosspresented on APCs(102) where TLR9 sensing of the AAV genome, MyD88, and IFNR were shown to be critical for productive transgene product-specific adaptive immune responses following IM AAV delivery.(11,19,84) An immunogenic hybrid capsid, rh32.”
BackgroundInfluentialToll-Like Receptor 9 Is Required for Opioid-Induced Microglia Apoptosis
He, L., Li, H., Chen, L., Miao, J., Jiang, Y., Zhang, Y., Xiao, Z., Hanley, G., Li, Y., Zhang, X., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018190 · Cited by 98
“It is widely accepted that TLR9 signaling mainly activates inflammatory responses, including proinflammatory cytokines [18,21,22,38].”
BackgroundAAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
M. Mitchell, A., C. Nicolson, S., K. Warischalk, J., & Jude Samulski, R. (2010) · Current Gene Therapy · doi:10.2174/156652310793180706 · Cited by 96
Ertl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
Coexpressed RIG-I Agonist Enhances Humoral Immune Response to Influenza Virus DNA Vaccine
Luke, J. M., Simon, G. G., Söderholm, J., Errett, J. S., August, J. T., Gale, M., Hodgson, C. P., & Williams, J. A. (2010) · Journal of Virology · doi:10.1128/jvi.01250-10 · Cited by 95
“Adaptive immune responses to AAV vectors, which do not activate cytoplasmic DNA receptor signaling pathways, are TLR9 dependent (74).”
BackgroundMonahan, P. E., Négrier, C., Tarantino, M., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85
“In nonparenchymal liver cells, such as Kupffer cells and liver sinusoidal endothelial cells (LSECs), the viral capsid activates innate immunity by binding to the Toll-like receptor (TLR) 2 [50], while the double-stranded (ds) DNA vector genome and unmethylated CpG motifs are recognized by TLR9 found in Kupffer cells […”
BackgroundSmith, C. J., Ross, N., Kamal, A., Kim, K. Y., Kropf, E., Deschatelets, P., Francois, C., Quinn, W. J., Singh, I., Majowicz, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999021 · Cited by 86
“A different type of dendritic cells, pDCs, was shown to secrete type I interferons in response to AAV (49), but did not participate directly in CD8 T cell priming (42).”
BackgroundRogers, G. L., Suzuki, M., Zolotukhin, I., Markusic, D. M., Morel, L. M., Lee, B., Ertl, H. C. J., & Herzog, R. W. (2015) · Journal of Innate Immunity · doi:10.1159/000369273 · Cited by 85
Rossi, A., Dupaty, L., Aillot, L., Zhang, L., Gallien, C., Hallek, M., Odenthal, M., Adriouch, S., Salvetti, A., & Büning, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-40071-1 · Cited by 85
Wright, J. F. (2021) · Biotechnology Journal · doi:10.1002/biot.202000022 · Cited by 82
Liver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81
Prasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
“Zhu et al demonstrated that the TLR9-MyD88–induced production of type I interferon is essential for the activation of the CD8 T cell response to the capsid and transgene-encoded product and is associated with the loss of transgene expression.(41) Another arm of innate immunity is the complement system.”
BackgroundEffect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy
Bertolini, T. B., Shirley, J. L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S. R. P., & Herzog, R. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672449 · Cited by 80
“In vitro studies showed TLR9-dependent induction of IFN I production in human pDCs pulsed with AAV vectors (8).”
BackgroundCodon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?
Wright, J. F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.026 · Cited by 80
Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Shirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79
“In contrast to DCs, other APCs are less critical for cross-priming of CD8 T cells, consistent with earlier in vitro data that pDCs are the cells that critically provide T1 IFN cytokines.(22,25) Therefore, T1 IFN production by pDCs in response to TLR9 activation promotes licensing of cDCs, which cross-present AAV capsi…”
BackgroundResultHigh Levels of Frataxin Overexpression Lead to Mitochondrial and Cardiac Toxicity in Mouse Models
Belbellaa, B., Reutenauer, L., Messaddeq, N., Monassier, L., & Puccio, H. M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.08.018 · Cited by 84
“In the current study, we did not investigate the potential involvement of the innate or adaptive immune response against the vector, transgene, and/or transduced cells.(35,36,52,53) It is likely that the treated mice developed a humoral response against the capsid, including neutralizing antibodies, as shown previousl…”
BackgroundGene therapy for liver diseases — progress and challenges
Zabaleta, N., Unzu, C., Weber, N. D., & González‐Aseguinolaza, G. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00729-0 · Cited by 80
Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy
D’Silva, A., Holland, S., Kariyawasam, D. S. T., Herbert, K., Barclay, P. G., Cairns, A. G., MacLennan, S. C., Ryan, M. M., Sampaio, H. A., Smith, N. J. C., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51519 · Cited by 76
“mechanism underlying this early transaminase elevation differs from the later peak which has been attributed to host adaptive immune responses.(20,22) Given the high vector doses involved, transient direct vector-mediated hepatotoxicity is plausible and merits further investigation.”
BackgroundHernandez-Chan, N. G., Bannon, M. J., Orozco-Barrios, C. E., Escobedo, L., Zamudio, S., De la Cruz, F., Gongora-Alfaro, J. L., Armendáriz-Borunda, J., Reyes-Corona, D., Espadas-Alvarez, A. J., et al. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0166-7 · Cited by 73
“Although viral gene therapy for PD has been under evaluation for a number of years [16, 62, 63], the availability of alternate gene transfer methods remains important considering the concerns with potential immune reactions to viral vectors [64, 65] and potential oncogenicity of viral vectors able to integrate the tra…”
BackgroundMücke, M. M., Fong, S., Foster, G. R., Lillicrap, D., Miesbach, W., & Zeuzem, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.029 · Cited by 81
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
“The TLR9MyD88 pathway is central in this association with both, humoral (51, 59, 62, 65) and cellular immunity (48, 51, 56, 60, 61, 63, 65).”
BackgroundJayandharan, G. R., Aslanidi, G., Martino, A. T., Jahn, S. C., Perrin, G. Q., Herzog, R. W., & Srivastava, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012753108 · Cited by 72
“More recently, it was shown that the innate immune response to AAV used the TLR9–MYD88 pathway, which generated a type I IFN response and was found to be essential for subsequent adaptive responses to vector and transgene product (16).”
BackgroundRetractedAdeno-associated Virus: A Key to the Human Genome?
Henckaerts, E., & Linden, R. M. (2010) · Future Virology · doi:10.2217/fvl.10.48 · Cited by 71
“It has been proposed that Toll-like receptor-dependent pathways are involved in the induction of an adaptive immunity to AAV [27].”
BackgroundImmunological barriers to haematopoietic stem cell gene therapy
Charlesworth, C. T., Hsu, I., Wilkinson, A. C., & Nakauchi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00698-0 · Cited by 74
Brennan, T. V., Lin, L., Brandstadter, J. D., Rendell, V. R., Dredge, K. S., Huang, X., & Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76566 · Cited by 73
Self-citationFriese, J., Geitmann, S., Holzwarth, D., Müller, N., Sassen, R., Baur, U., Adler, K., & Kirschner, J. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200593 · Cited by 73
“AAV9 has been shown to stimulate dendritic cells via TLR9 with activation of adaptive immunity [25].”
BackgroundMays, L. E., Wang, L., Lin, J., Bell, P., Crawford, A., Wherry, E. J., & Wilson, J. M. (2014) · Molecular Therapy · doi:10.1038/mt.2013.134 · Cited by 62
Barlan, A. U., Danthi, P., & Wiethoff, C. M. (2011) · Virology · doi:10.1016/j.virol.2011.01.019 · Cited by 65
“, 2007), and parvovirus (Zhu et al., 2009) are recognized by the host while entering cells although the exact details have been incompletely defined.”
The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer
Xiang, Z., Kurupati, R. K., Li, Y., Kuranda, K., Zhou, X., Mingozzi, F., High, K. A., & Ertl, H. C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.014 · Cited by 67
TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy
Ashley, S. N., Somanathan, S., Giles, A. R., & Wilson, J. M. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103997 · Cited by 67
“This observation was reported in studies involving ex vivo stimulation of plasmacytoid dendritic cells with AAV2 [17] or i.”
ResultInfluentialAdeno-Associated Virus Genome Interactions Important for Vector Production and Transduction
Maurer, A. C., & Weitzman, M. D. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.069 · Cited by 76
“TLR9-mediated recognition of the vector genome triggers type I interferon production irrespective of transgene sequence.(103) This response is reported to be substantially greater for scAAV genomes,(104) although the canonical ligand for TLR9 activation is ssDNA.”
BackgroundQuantification of CpG motifs in rAAV genomes: Avoiding the toll
Wright, J. F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.07.006 · Cited by 65
Innate Immune Response to Viral Vectors in Gene Therapy
Wang, Y., & Shao, W. (2023) · Viruses · doi:10.3390/v15091801 · Cited by 68
López-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 70
“…the capsid, the host cells also recognize AAV DNA via Toll-like receptor 9 (TLR9) to induce innate immunity and a stronger adaptive immune response [216] or via antigen cross-presentation by MHC class I or II, following intracellular proteasomal degradation of AAV capsids or therapeutic proteins…”
BackgroundRaupp, C., Naumer, M., Müller, O. J., Gurda, B. L., Agbandje-McKenna, M., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.00209-12 · Cited by 64
“AAV vectors show generally a low innate immunity, as well as low efficiency to transduce professional antigen-presenting cells (87), although recent studies warrant a more differentiated view of the immune response to AAV-mediated gene transfer (8, 22, 23, 26, 29, 32, 33, 37, 50, 65, 84, 88).”
ResultHuman Glucocorticoid Receptor β Regulates Gluconeogenesis and Inflammation in Mouse Liver
He, B., Cruz-Topete, D., Oakley, R. H., Xiao, X., & Cidlowski, J. A. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00908-15 · Cited by 62
“Recent studies demonstrated that AAV infection of purified hepatic Kupffer cells in vitro 520 failed to produce significant level of type I IFN and IL-6, in contrast to infection with adenovirus 521 (33) and that gene expression of STAT1 and SOCS1 remained unchanged in AAV-injected 522 mouse liver compared to the cont…”
Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?
Wagner, D. L., Peter, L., & Schmueck-Henneresse, M. (2021) · Gene Therapy · doi:10.1038/s41434-021-00232-2 · Cited by 63
Gross, D., Tedesco, N., Leborgne, C., & Ronzitti, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857276 · Cited by 66
“Early findings supported the involvement of the innate signaling in the formation of the humoral immune response to AAV vectors (94).”
BackgroundRecognition of Virus Infection and Innate Host Responses to Viral Gene Therapy Vectors
Shayakhmetov, D. M., Di Paolo, N. C., & Mossman, K. L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.124 · Cited by 60
Viral vectors as vaccine carriers
Ertl, H. C. J. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.06.001 · Cited by 65
Metadata
- Authors
- Zhu, J., Huang, X., & Yang, Y.
- Affiliations
- Duke Medical Center (US)
- Duke University (US)
- Corresponding author
- Yang, Yiping
- Venue
- Journal of Clinical Investigation
- Published
- 2009-08-03
- Volume
- 119
- Issue
- 8
- Pages
- 2388-2398
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2719948
- OpenAlex
- W2043149070
- Semantic Scholar
- 9808ef8c0218096852d97ab403f3e3a9feeb2215
- Cited by
- 330
- References
- 73
- Citations by year
- 2026: 23 · 2025: 20 · 2024: 26 · 2023: 31 · 2022: 29 · 2021: 27 · 2020: 29 · 2019: 24 · 2018: 16 · 2017: 17 · 2016: 7 · 2015: 15 · 2014: 10 · 2013: 15 · 2012: 11
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CA047741)
- University of North Carolina at Chapel Hill
- National Cancer Institute (CA111807, CA047741, P01CA047741, R01CA111807)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, AAV gene therapy, TLR9, MyD88, type I interferon, plasmacytoid dendritic cells, innate immunity, adaptive immune response, CD8+ T cells, AAV capsid, neutralizing antibodies, transgene expression, immunogenicity
- MeSH terms
- Dependovirus, Animals, Cells, Cultured, Dendritic Cells, Genetic Vectors, Humans, Immunity, Innate, Interferon Type I, Mice, Inbred BALB C, Mice, Inbred C57BL, Genetic Therapy, Signal Transduction, CD8-Positive T-Lymphocytes, Transgenes, Toll-Like Receptor 9, Mice, Myeloid Differentiation Factor 88
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.